Arginine deprivation in cancer therapy

Lynn G. Feun, Macus Tien Kuo, Niramol Savaraj

Research output: Contribution to journalReview articlepeer-review

50 Scopus citations


Purpose of review There has been an increased and renewed interest in metabolic therapy for cancer, particularly Arg deprivation. The purpose of this review is to highlight recent studies that focus on Arg-dependent malignancies with Arginine (Arg)-degrading enzymes, including arginase and Arg deiminase.

Recent findings New developments in this area include understanding of the role of most significantly downregulated gene regulating amino acid metabolism, argininosuccinate synthetase and its expression and therapeutic relevance in different tumors. Recent studies have also shed light on the mechanism of tumor cell death with Arg deprivation, with arginase and pegylated Arg deiminase. Particularly important is understanding the mechanism of resistance that cancers develop after such drug exposure. Finally, recent clinical trials have been performed or are ongoing to use Arg deprivation as treatment for advanced malignancies.

Summary Arg deprivation is a promising approach for the treatment of various malignancies.

Original languageEnglish (US)
Pages (from-to)78-82
Number of pages5
JournalCurrent Opinion in Clinical Nutrition and Metabolic Care
Issue number1
StatePublished - Jan 12 2015


  • Arg
  • Arg deiminase
  • Arginase
  • Cancer

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics


Dive into the research topics of 'Arginine deprivation in cancer therapy'. Together they form a unique fingerprint.

Cite this